LAVA Therapeutics NV

LAVA Therapeutics NV — Investor Presentation (September 2022)

35 slides from LAVA Therapeutics NV's investor presentation, Sep 30, 2022

  1. Slide 1: Fighting Cancer with Precision Gammabody Platform Corporate Presentation

    1 Fighting Cancer with Precision Gammabody ™ Platform Corporate Presentation September 2022

  2. Slide 2: Legal Disclosure: Forward-looking Statements

    2 Legal Disclosure: Forward - looking Statements This presentation contains forward - looking statements, including with respect to the company’s anticipated growth and clinical development plans, including the timing of clinical trials .. Words such as “anticipate,” “believe,” “could,” “will,” “may

  3. Slide 3: Investment Highlights

    3 Investment Highlights Clinical - Stage Company Developing Bispecific Gamma Delta T Cell Engagers © LAVA Therapeutics 2022 • Gammabody ™ Platform - Bispecific antibodies linking V  9V  2 T cells to tumor targets to l everage the unique anti - tumor potential of V  9V  2 T cells • Strongly enhan

  4. Slide 4: Differentiated Gammabody Pipeline in Hematologic & Solid Tumor Indications

    4 Differentiated Gammabody ™ Pipeline in Hematologic & Solid Tumor Indications Solid Tumor Hematologic malignancy MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate - specific membrane antigen EGFR: epidermal growth factor receptor mCRPC : metastatic ca

  5. Slide 5: Established Leadership with Proven Experience in Drug Discovery & Development

    5 Established Leadership with Proven Experience in Drug Discovery & Development Ton Adang, PhD CDO Paul Parren, PhD EVP, Head of R&D Hans van der Vliet, MD, PhD CSO Steve Hurly, MSc, MBA President & CEO • 25+ years leadership experience in life sciences industry • Former President & CEO, Sesen Bio,

  6. Slide 6: Gamma Delta T Cells

    6 Gamma Delta T Cells Uniquely suited for an anti - cancer T cell engager approach V  9V  2 T Cells

  7. Slide 7: Vγ9Vδ2 T Cells Uniquely Positioned to Leverage Innate & Adaptive Immunity

    7 V  9V  2 T Cells are Uniquely Positioned to Leverage Innate & Adaptive Immunity V  9V  2 T cells are an abundant, homogeneous effector cell population associated with positive outcomes in cancer patients Adaptive Immunity Innate Immunity Yeung MM, et al. Gut 2000; 47:215 Kimura Y, et al. Cance

  8. Slide 8: Gamma Delta T Cells Present in Many Cancers & Correlated With Favorable Prognosis

    8  T Cells Present in Many Cancers & Correlated With Favorable Prognosis Adapted from Tosolini M et al. Oncoimmunology 2017; 6, e1284723  T cells indicate highest correlation with favorable outcome among all leukocyte subsets analyzed V  9V  2 T cells are present across a wide array of hematol

  9. Slide 9: LAVA's Proprietary Gammabody Platform

    9 LAVA’s Proprietary Gammabody ™ Platform Bispecific Gamma Delta T Cell Engagers

  10. Slide 10: Systemic Activation of Vγ9Vδ2 Cells Showed Promise

    10 Systemic Activation of V  9V  2 T Cells Showed Promise • Systemic activation and proliferation via treatment with V  9V  2 T cell - based therapy (synthetic phosphoantigens ( BrHPP ) / aminobisphosphonates ± low - dose IL - 2) Early attempts with V  9V  2 T cell - based therapy showed promi

  11. Slide 11: Off-the-Shelf Gammabody Platform Directing Vγ9Vδ2 Cells to Cancer Cells

    11 Off - the - Shelf Gammabody ™ Platform: Enhances Innate Tumor Recognition by Directing V  9V  2 T Cells to the Cancer Cells LAVA’s Gammabody ™ adds tumor antigen - specific recognition, while retaining stress signal recognition, to target and activate V  9V  2 T cells to induce both direct tu

  12. Slide 12: Cascade Response – Potential Translation to Favorable Therapeutic Window

    12 Cascade Response – Potential Translation to Favorable Therapeutic Window Efficacy: Safety: In addition to direct tumor cell killing , V  9 V  2 T cells have the potential to orchestrate an immunological cascade response that includes activation of innate and adaptive immune cells in the tumor m

  13. Slide 13: Potent Killing of Cancer Cells in Preclinical Models

    13 Potent Killing of Cancer Cells in Preclinical Models Highly Potent Durable Dose Dependent and Serial Killing Conditional Activation EGFR Gammabody ™ - Induced Cytotoxicity CD1d Gammabody ™ Triggers Lysis of CCRF - CEM Tumor Cells Killing of Primary Colorectal Cancer Cells by EGFR Gammabody ™ Sust

  14. Slide 14: Expansion & Cascade Response Without Treg Activation in Preclinical Models

    14 Expansion & Cascade Response Without Treg Activation in Preclinical Models Gammabody ™ can induce robust gamma delta T cell expansion and can amplify the anti - tumor immune response via downstream activation of other immune cells while avoiding co - activation of immunosuppressive T cells such a

  15. Slide 15: Gammabody Can Selectively Kill Cancer Cells While Sparing Healthy Cells

    15 Gammabody ™ Can Selectively Kill Cancer Cells W hile Sparing Healthy Cells in Hematologic Malignancy and Solid Tumor models • 2:1 ratio (  T cells : Target cells) • Similar CD20 expression levels on C1R neo and B - cells CD20 Gammabody ™ Mediated Killing PSMA Gammabody ™ Mediated Killing Prefer

  16. Slide 16: Fully Cross-Reactive Surrogates Well-Tolerated in Non-Human Primates

    16 Fully Cross - Reactive  bsTCEs are Well - Tolerated in Non - Human Primates • Mild to no clinical signs of toxicity • Low cytokine spike, which did not result in CRS • No clinical chemistry abnormalities • No histopathological abnormalities • Gammabody ™ detectable on peripheral blood and lymph

  17. Slide 17: LAVA-051 Activates Vγ9Vδ2 T Cells and iNKT Cells by Targeting CD1d

    17 LAVA - 051 Activates  T Cells and iNKT Cells by Targeting CD1d for the Treatment of CLL, MM & AML

  18. Slide 18: LAVA-051: First-in-Class Gammabody Targeting CD1d

    18 LAVA - 051: First - in - Class Gammabody ™ Targeting CD1d • Principal Mechanism of Action ( MoA ): Targets and activates V  9V  2 T cells in the presence of CD1d - expressing tumor cells • Secondary MoA : Activates iNKT cells against CD1d - expressing tumor cells ‒ Direct cytotoxicity against C

  19. Slide 19: LAVA-051: Targeting CD1d for Hematological Cancers

    19 LAVA - 051: Targeting CD1d for Hematological Cancers CD1d is expressed on tumors cells in a high proportion of patients with CLL, MM & AML CD1d expression (MF index) Isotype Isotype Isotype 0.5 1 2 4 8 16 32 64 128 N=39 N=51 N=85 AML MM CLL © LAVA Therapeutics 2022 Data on file: LAVA Therapeutics

  20. Slide 20: LAVA-051 Phase 1/2a Initiated in Hematological Malignancies

    20 CLL AND MM AML (highest dose levels only) Optional adjustments: • Dosing frequency • Dose level • # cohorts CLL (n=20) MM (n=20) Twice - weekly dosing AML (n=20) LAVA - 051 Phase 1/2a Initiated in Hematological Malignancies Phase 1 first 4 cohorts dose escalation data presented at ASCO 2022; Addi

  21. Slide 21: LAVA-051 Phase 1/2a: Extensive Biomarker Analysis

    21 Biomarker analysis to validate whether LAVA’s Gammabody ™ platform performs in humans as predicted based on preclinical data LAVA - 051 Phase 1/2a: Extensive Biomarker Analysis Pharmacodynamics Cytokines (IL - 1β, IL - 2, IL - 6, IL - 8, TNF - α, IFN - γ, GM - CSF) B inding of LAVA - 051: V  9V

  22. Slide 22: LAVA-051 Patient characteristics and time on treatment

    22 LAVA - 051 - Patient characteristics and time on treatment MM/CLL 3/3 Male/Female 5/1 Median age (range) 66 (60 - 75) Prior therapies, median (range) – MM/CLL 5 (4 - 6) 4 (3 - 5) DLT period PD PD PD PD COVID COVID © LAVA Therapeutics 2022

  23. Slide 23: LAVA-051 Adverse events

    23 LAVA - 051 - Adverse events NS = not suspected; S = suspected A : Drug hypersensitivity Gr3 reported for CLL patient to allopurinol administered as TLS prophylaxis; allergy to allopurinol con firmed through repeat occurrence to single agent prophylaxis. B : Fever Gr2 reported for CLL patient in c

  24. Slide 24: LAVA-051 Pharmacodynamics

    24 LAVA - 051 - Pharmacodynamics • V  9 V  2 T cell activation markers (CD 25 and CD 69 ) consistently upregulated following dosing, in each dose cohort • Maximum measured V  9 V  2 T cell receptor occupancy (RO) increased with higher dose cohorts • iNKT cell activation was assessable, and obser

  25. Slide 25: LAVA-051 Potential signs of activity

    25 LAVA - 051 – Potential signs of activity 0 25 50 75 100 125 0.01 0.1 1 Treatment days Cell count (x10 9 /L) Lymphocytes Clonal B cells R/R = Relapsed/Refractory; iwCLL = international workshop on C hronic Lymphocytic L eukemia. Permission for photo obtained. MM • High risk MM patient ( 45  g) •

  26. Slide 26: Conclusions

    26 Conclusions • LAVA - 051 is the first of a novel class of bispecific  T cell engagers with expected broad therapeutic window – Bispecific single domain antibody engaging CD 1 d and V  2 - TCR chain of V  9 V  2 - T cells to mediate potent killing – Low potential for CRS observed in preclinic

  27. Slide 27: LAVA-1207 Activates Vγ9Vδ2 T Cells by Targeting PSMA for mCRPC

    27 LAVA - 1207 Activates  T Cells by Targeting PSMA for the Treatment of mCRPC

  28. Slide 28: LAVA-1207: Targeting PSMA for Prostate Cancer

    28 LAVA - 1207: Targeting PSMA for Prostate Cancer PSMA + tumor cells LAVA - 1207 VHH - Fc ~80kD V  9V  2 T cells • Specifically targets and mediates activation of V  9 V  2 T cells against PSMA - expressing tumor cells • PSMA is a well - validated tumor target ‒ Mediates PSMA - dependent activa

  29. Slide 29: LAVA-1207 Phase 1/2a in Metastatic Castration-Resistant Prostate Cancer

    29 LAVA - 1207 Phase 1/2a in Metastatic Castration - Resistant Prostate Cancer ( mCRPC ) Therapy Refractory mCRPC Optional Adjustments: • Dosing frequency • Dose level • # cohorts Therapy Refractory mCRPC (n=30) Dosing: Every 2 Weeks LAVA - 1207 Phase 1/2a Initiated; Patient Recruitment Underway Dos

  30. Slide 30: Key Preclinical Programs

    30 Key Preclinical Programs

  31. Slide 31: Potential for LAVA-1223 Across EGFR-Expressing Solid Tumors

    31 Potential for LAVA - 1223 Across a Number of EGFR - Expressing Solid Tumors Data on file: LAVA Therapeutics N.V. and Janssen Biotech Inc. 0 20 40 60 80 100 Bladder Breast Colon Glioma Head & Neck NSCLC Ovarian Pancreatic RCC Percentage overexpression range EGFR Expression by Tumor Type (Range) Su

  32. Slide 32: LAVA-1266 Shows Promise for Hematological Malignancies

    32 LAVA - 1266 Shows Promise for Hematological Malignancies 0.01 0.1 1 10 100 1000 0 20 40 60 80 100 CD123 Gammabody TM Concentration [pM] Specific cell death of primary AML cells (%) EC50 ~ 8 pM 0.01 0.1 1 10 100 1000 0 20 40 60 80 100 CD123 Gammabody TM Concentration [pM] THP-1 cell line cytotoxic

  33. Slide 33: dp) —@® (Ss {e) _— ep) & =

    dp) —@® (Ss {e) _— ep) & =

  34. Slide 34: Two Lead Programs in Clinic with Near-Term Milestones

    34 • 3L+ mCRPC pts • Adoptive FIH study design, dose escalation • Key data: Safety, initial anti - tumor activity, estimation of therapeutic window • Initial study in relapsed/refractory MM, CLL; relapsed/refractory AML added at biological relevant dose(s) • Adoptive FIH study design, dose escalatio

  35. Slide 35: September

    35 Corporate Presentation September 2022

LAVA Therapeutics — Investor Presentation (September 2022) on 6ix